Participation in PDS Biotech

0

FLORHAM PARK, NJ, May 17, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the company’s Versamune® and Infectimune™ T-cell activating technologies, announced today that its management will present at the HC Wainwright Global Investment Conference and LD Micro Invitational and will participate in the UBS Healthcare Virtual One-on-One Day.

HC Wainwright Global Investment Conference
Date: Tuesday 24 May 2022
Time: 7:00 a.m. EDT
Investors can register for the conference here

UBS Healthcare Virtual One on One Day
Date: Wednesday 1 June 2022

LD Micro Invitational Conference
Date: Wednesday 8 June 2022
Time: 7:30 a.m. PDT
Virtual viewers: Live broadcast

Following the conferences, a webcast replay of the presentations will be available on the Investors section of the Company’s website, PDS biotechnology.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted immunotherapies for cancer and infectious diseases based on the company’s Versamune® and Infectimune™ T-cell activation technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current induction-based immunotherapy in vivo, large quantities of high-quality, highly potent polyfunctional tumor-specific CD4+ helper and CD8+ killer T cells. PDS Biotech has developed multiple therapies based on combinations of Versamune® and disease-specific antigens designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products treat multiple cancers, including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar), breast, colon, lung, prostate and cancer ovarian cancer.

Our Infectimune™-based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also potent T-cell responses, including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter @PDSBiotech.

Investor contact:
Rich Cockrell
CG capital
Telephone: +1 (404) 736-3838
[email protected]

PDS-Biotechnology-Corporation.png

Share.

Comments are closed.